Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. J Med Virol. 2023 01; 95(1):e28157.
View in:
PubMed
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 07 19; 12(7):110.
View in:
PubMed
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 2022 04; 36(4):1048-1057.
View in:
PubMed
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes. Eur J Haematol. 2021 Nov; 107(5):553-565.
View in:
PubMed
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2022 01; 36(1):210-220.
View in:
PubMed
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
View in:
PubMed
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leuk Lymphoma. 2021 10; 62(10):2457-2465.
View in:
PubMed
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI Insight. 2021 04 08; 6(7).
View in:
PubMed
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
View in:
PubMed
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
View in:
PubMed
Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167.
View in:
PubMed
Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020 Aug; 98(8):483-489.
View in:
PubMed
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
View in:
PubMed
Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
View in:
PubMed
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
View in:
PubMed
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
View in:
PubMed
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
View in:
PubMed
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
View in:
PubMed
Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2019 Jul; 121(3):282.
View in:
PubMed
Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study. Eur J Haematol. 2019 Apr; 102(4):341-350.
View in:
PubMed
Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res. 2018 09; 72:34-44.
View in:
PubMed
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther. 2018; 11:175-182.
View in:
PubMed
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. 2018 02 06; 57(5):477-478.
View in:
PubMed
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6.
View in:
PubMed
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984.
View in:
PubMed
Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in:
PubMed
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
View in:
PubMed
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
View in:
PubMed
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650.
View in:
PubMed
Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 01; 25(3):838-846.
View in:
PubMed
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 15; 25(4):1320-1328.
View in:
PubMed
Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in:
PubMed
Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51.
View in:
PubMed
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17; 7(20):29131-42.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in:
PubMed
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81.
View in:
PubMed
Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells. BMC Cancer. 2015 Oct 26; 15:803.
View in:
PubMed
Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 09.
View in:
PubMed
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther. 2015 Oct; 14(10):2249-59.
View in:
PubMed
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015 May 14; 125(20):3133-43.
View in:
PubMed
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563.
View in:
PubMed
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Arch Toxicol. 2014 Dec; 88(12):2233-42.
View in:
PubMed
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95.
View in:
PubMed
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37.
View in:
PubMed
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
View in:
PubMed
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
View in:
PubMed
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
View in:
PubMed
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol. 2013 Oct; 20(10):1221-3.
View in:
PubMed
Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets. 2013 Sep; 13(7):735-48.
View in:
PubMed
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013 Oct 18; 8(10):2145-50.
View in:
PubMed
Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8.
View in:
PubMed
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis. Curr Med Res Opin. 2013 Jun; 29(6):623-31.
View in:
PubMed
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
View in:
PubMed
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
View in:
PubMed
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin. 2012 Jul; 28(7):1155-62.
View in:
PubMed
Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett. 2012 Aug 15; 22(16):5297-302.
View in:
PubMed
An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRa and kit. Bioorg Med Chem Lett. 2012 Jul 15; 22(14):4579-84.
View in:
PubMed
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44.
View in:
PubMed
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012 May; 26(5):985-90.
View in:
PubMed
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
View in:
PubMed
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012 Apr; 26(4):708-15.
View in:
PubMed
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012 Mar; 26(3):481-9.
View in:
PubMed
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
View in:
PubMed
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
View in:
PubMed
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010 Dec; 26(12):2861-9.
View in:
PubMed
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct; 1(10):1021-32.
View in:
PubMed
Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9.
View in:
PubMed
Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010 Sep; 9(9):2468-77.
View in:
PubMed
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer. 2010 Aug; 1(8):822-35.
View in:
PubMed
Drug resistance in mutant FLT3-positive AML. Oncogene. 2010 Sep 16; 29(37):5120-34.
View in:
PubMed
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
View in:
PubMed
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia. 2010 Jul; 24(7):1375-8.
View in:
PubMed
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16.
View in:
PubMed
The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem. 2010 May 07; 285(19):14356-65.
View in:
PubMed
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
View in:
PubMed
Wnt/ß-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3ß Dependent Manner. Genes Cancer. 2010 Feb; 1(2):164-76.
View in:
PubMed
A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. Mol Cell Proteomics. 2010 May; 9(5):780-90.
View in:
PubMed
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010 Jan 19; 102(2):351-60.
View in:
PubMed
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in:
PubMed
JAK2 gets histone H3 rolling. Cancer Cell. 2009 Nov 06; 16(5):365-6.
View in:
PubMed
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9.
View in:
PubMed
Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. J Clin Oncol. 2009 May 20; 27(15_suppl):7090.
View in:
PubMed
Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelegenous leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):7092.
View in:
PubMed
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9.
View in:
PubMed
Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest. 2008 Nov; 118(11):3564-73.
View in:
PubMed
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70.
View in:
PubMed
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1121-9.
View in:
PubMed
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96.
View in:
PubMed
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 01; 111(7):3751-9.
View in:
PubMed
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 01; 111(7):3723-34.
View in:
PubMed
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13.
View in:
PubMed
The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood. 2007 Nov 15; 110(10):3618-23.
View in:
PubMed
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007 Jul; 6(7):1951-61.
View in:
PubMed
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007 May; 7(5):345-56.
View in:
PubMed
The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem. 2007 Apr 20; 282(16):11969-81.
View in:
PubMed
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007 Jun 01; 109(11):5011-5.
View in:
PubMed
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007 Mar; 117(3):730-8.
View in:
PubMed
NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia. 2007 Mar; 21(3):462-71.
View in:
PubMed
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 01; 109(5):2112-20.
View in:
PubMed
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006 Dec; 131(6):1734-42.
View in:
PubMed
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51.
View in:
PubMed
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19; 94(12):1765-9.
View in:
PubMed
Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006 Jun 30; 281(26):18177-83.
View in:
PubMed
The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 2006 Mar 15; 20(6):675-88.
View in:
PubMed
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 01; 107(3):1237-8.
View in:
PubMed
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15; 24(56):8259-67.
View in:
PubMed
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 2005 Nov 24; 24(53):7882-92.
View in:
PubMed
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74.
View in:
PubMed
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15; 106(10):3377-9.
View in:
PubMed
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005 Nov 01; 106(9):3206-13.
View in:
PubMed
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7.
View in:
PubMed
Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005 Jul 06; 24(13):2391-402.
View in:
PubMed
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
View in:
PubMed
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15; 106(2):721-4.
View in:
PubMed
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005 Jun; 19(8):960-2.
View in:
PubMed
Interaction maps for kinase inhibitors. Nat Biotechnol. 2005 Mar; 23(3):308-9.
View in:
PubMed
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41.
View in:
PubMed
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 2004 Dec; 18(12):1951-63.
View in:
PubMed
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
View in:
PubMed
Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol. 2004 Oct; 14(5):348-56.
View in:
PubMed
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
View in:
PubMed
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004 Sep 15; 64(18):6385-9.
View in:
PubMed
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7.
View in:
PubMed
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30.
View in:
PubMed
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 01; 105(1):54-60.
View in:
PubMed
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in:
PubMed
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest. 2004 Jun; 113(12):1784-91.
View in:
PubMed
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene. 2004 Apr 22; 23(19):3338-49.
View in:
PubMed
Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene. 2004 Mar 17; 328:153-65.
View in:
PubMed
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem. 2004 Mar; 4(3):285-99.
View in:
PubMed
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3130-5.
View in:
PubMed
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004 Jun 15; 103(12):4622-9.
View in:
PubMed
The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol. 2004 Feb; 79(2):138-46.
View in:
PubMed
FLT3 tyrosine kinase as a target in acute leukemias. Hematol J. 2004; 5 Suppl 3:S188-90.
View in:
PubMed
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90.
View in:
PubMed
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004 Apr 01; 103(7):2802-5.
View in:
PubMed
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma. 2003 Nov; 44(11):1987-96.
View in:
PubMed
Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003 Oct; 6(5):231-8.
View in:
PubMed
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
View in:
PubMed
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
View in:
PubMed
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
View in:
PubMed
Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr; 40(2 Suppl 2):4-10.
View in:
PubMed
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
View in:
PubMed
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
View in:
PubMed
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003 Feb; 33(2):208-13.
View in:
PubMed
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40.
View in:
PubMed
Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 82-101.
View in:
PubMed
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003 Jan; 23(2):655-64.
View in:
PubMed
Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002 Nov; 22(21):7688-700.
View in:
PubMed
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
View in:
PubMed
The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 01; 100(5):1532-42.
View in:
PubMed
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002 Nov 15; 100(10):3767-75.
View in:
PubMed
Role of FLT3 in leukemia. Curr Opin Hematol. 2002 Jul; 9(4):274-81.
View in:
PubMed
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92.
View in:
PubMed
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002 Jun; 1(5):433-43.
View in:
PubMed
Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002 May 13; 21(21):3314-33.
View in:
PubMed
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem. 2002 Jun 07; 277(23):20887-94.
View in:
PubMed
Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J Neurosci Res. 2002 Mar 01; 67(5):618-24.
View in:
PubMed
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
View in:
PubMed
Resistance to targeted therapy in leukaemia. Lancet. 2002 Feb 09; 359(9305):458-9.
View in:
PubMed
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15; 99(2):664-71.
View in:
PubMed
Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 2001 Oct 15; 98(8):2291.
View in:
PubMed
The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem. 2001 Nov 30; 276(48):44889-97.
View in:
PubMed
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia. 2001 Sep; 15(9):1424-32.
View in:
PubMed
Notch receptors and hematopoiesis. Exp Hematol. 2001 Sep; 29(9):1041-52.
View in:
PubMed
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
View in:
PubMed
Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother Pharmacol. 2001 Aug; 48 Suppl 1:S11-6.
View in:
PubMed
Point mutations in the FLT3 gene in AML. Blood. 2001 Apr 15; 97(8):2193A-2193.
View in:
PubMed
ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001 Apr 15; 97(8):2440-8.
View in:
PubMed
Investigator profile: James D. Griffin M.D. interviewed by Vicki P. Glaser. J Hematother Stem Cell Res. 2001 Apr; 10(2):209-14.
View in:
PubMed
Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 Apr; 73(3):278-91.
View in:
PubMed
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat. 2001 Feb; 4(1):22-8.
View in:
PubMed
BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
View in:
PubMed
MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 2000 Dec; 26(4):484-9.
View in:
PubMed
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci. 2000 Dec; 113 Pt 23:4313-8.
View in:
PubMed
The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood. 2000 Nov 01; 96(9):3294-5.
View in:
PubMed
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
View in:
PubMed
Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000 Sep 15; 96(6):2269-76.
View in:
PubMed
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
View in:
PubMed
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
View in:
PubMed
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000 Jun 01; 95(11):3498-505.
View in:
PubMed
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25.
View in:
PubMed
The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem. 2000 Jan 14; 275(2):1405-13.
View in:
PubMed
Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia. 2000 Jan; 14(1):169-82.
View in:
PubMed
The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem. 1999 Dec 31; 274(53):37525-32.
View in:
PubMed
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
View in:
PubMed
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
View in:
PubMed
Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. J Biol Chem. 1999 Nov 19; 274(47):33522-30.
View in:
PubMed
BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999 Nov; 19(11):7473-80.
View in:
PubMed
Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng. 1999 Sep; 12(9):779-85.
View in:
PubMed
Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 03; 18(22):3343-53.
View in:
PubMed
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.
View in:
PubMed
Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann N Y Acad Sci. 1999 Apr 30; 872:305-12; discussion 312-3.
View in:
PubMed
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
View in:
PubMed
Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. Oncogene. 1998 Dec 10; 17(23):2961-71.
View in:
PubMed
The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. Blood. 1998 Nov 15; 92(10):3848-56.
View in:
PubMed
Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. Am J Physiol. 1998 03; 274(3):R783-9.
View in:
PubMed
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem. 1997 Dec 26; 272(52):33373-6.
View in:
PubMed
Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1997 Dec 15; 90(12):4759-66.
View in:
PubMed
Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood. 1997 Dec 15; 90(12):4687-98.
View in:
PubMed
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1997 Dec; 25(13):1367-77.
View in:
PubMed
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 06; 15(19):2379-84.
View in:
PubMed
A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. J Clin Invest. 1997 Oct 01; 100(7):1708-15.
View in:
PubMed
BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57.
View in:
PubMed
Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells. J Biol Chem. 1997 Jun 27; 272(26):16421-30.
View in:
PubMed
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6.
View in:
PubMed
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11; 272(15):10248-53.
View in:
PubMed
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
View in:
PubMed
Determinants of hypothalamic neuronal thermosensitivity. Ann N Y Acad Sci. 1997 Mar 15; 813:133-8.
View in:
PubMed
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85.
View in:
PubMed
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
View in:
PubMed
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
View in:
PubMed
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6.
View in:
PubMed
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11681-6.
View in:
PubMed
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
View in:
PubMed
Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. J Neurosci. 1996 Oct 01; 16(19):6246-54.
View in:
PubMed
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996 Sep 19; 13(6):1147-52.
View in:
PubMed
Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996 Jul 15; 98(2):521-8.
View in:
PubMed
Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines. J Immunol. 1996 Jul 15; 157(2):534-40.
View in:
PubMed
Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996 Jul; 94(1):5-16.
View in:
PubMed
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996 Mar 01; 183(3):811-20.
View in:
PubMed
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46.
View in:
PubMed
B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in:
PubMed
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb; 24(2):310-3.
View in:
PubMed
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21; 11(6):1149-55.
View in:
PubMed
Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci U S A. 1995 Sep 12; 92(19):8665-9.
View in:
PubMed
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
View in:
PubMed
Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in:
PubMed
Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995 May; 49(1):29-38.
View in:
PubMed
The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 1995 Mar 10; 270(10):4979-82.
View in:
PubMed
Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene. 1995 Feb 16; 10(4):751-5.
View in:
PubMed
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia. 1995 Feb; 9(2):295-301.
View in:
PubMed
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 1995 Jan 16; 14(2):257-65.
View in:
PubMed
A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. J Biol Chem. 1994 Dec 02; 269(48):30173-80.
View in:
PubMed
CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 01; 180(5):1665-73.
View in:
PubMed
Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells. J Biol Chem. 1994 Oct 07; 269(40):24602-7.
View in:
PubMed
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994 Oct; 22(11):1111-7.
View in:
PubMed
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994 Sep 16; 269(37):22925-8.
View in:
PubMed
Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. Blood. 1994 Aug 01; 84(3):789-94.
View in:
PubMed
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994 Jul; 14(7):4335-41.
View in:
PubMed
Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7. Leukemia. 1994 May; 8(5):740-8.
View in:
PubMed
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
View in:
PubMed
p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem. 1994 Feb 25; 269(8):5764-9.
View in:
PubMed
rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. J Biol Chem. 1994 Feb 18; 269(7):5387-90.
View in:
PubMed
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18; 269(7):5016-21.
View in:
PubMed
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 1994 Jan; 9(1):149-56.
View in:
PubMed
Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A. 1993 Oct 15; 90(20):9571-5.
View in:
PubMed
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
View in:
PubMed
Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102.
View in:
PubMed
The human granulocyte-macrophage colony-stimulating factor receptor is capable of initiating signal transduction in NIH3T3 cells. EMBO J. 1993 Apr; 12(4):1647-56.
View in:
PubMed
Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem. 1993 Feb 25; 268(6):4113-9.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line. J Cell Physiol. 1992 Oct; 153(1):176-86.
View in:
PubMed
Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1992 Oct 01; 80(7):1736-42.
View in:
PubMed
Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I. J Biol Chem. 1992 Aug 25; 267(24):17121-7.
View in:
PubMed
Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992 Aug 15; 80(4):1083-9.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood. 1992 Jun 01; 79(11):2880-7.
View in:
PubMed
Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36.
View in:
PubMed
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 01; 79(9):2215-20.
View in:
PubMed
Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol. 1992 May; 20(4):442-8.
View in:
PubMed
Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. J Cell Physiol. 1992 Mar; 150(3):484-92.
View in:
PubMed
The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992 Mar 01; 89(5):1795-8.
View in:
PubMed
Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells. Cancer Res. 1992 Feb 01; 52(3):566-70.
View in:
PubMed
Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 1992 Feb 01; 79(3):657-65.
View in:
PubMed
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 1991 Dec 01; 78(11):2834-40.
View in:
PubMed
Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 01; 78(11):2791-808.
View in:
PubMed
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991 Dec 01; 78(11):2962-8.
View in:
PubMed
Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. Blood. 1991 Oct 15; 78(8):1928-35.
View in:
PubMed
Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol. 1991 Oct 15; 147(8):2565-73.
View in:
PubMed
CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991 Oct 01; 78(7):1834-41.
View in:
PubMed
Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene. 1991 Aug; 6(8):1343-6.
View in:
PubMed
Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 1991 Jun 01; 77(11):2404-12.
View in:
PubMed
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15; 77(10):2242-50.
View in:
PubMed
Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia. 1991 Apr; 5(4):300-8.
View in:
PubMed
Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991 Mar 01; 77(5):1033-43.
View in:
PubMed
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8.
View in:
PubMed
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature. 1991 Feb 21; 349(6311):691-4.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. Blood. 1991 Jan 15; 77(2):243-8.
View in:
PubMed
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem. 1991 Jan 05; 266(1):490-5.
View in:
PubMed
cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science. 1990 Nov 09; 250(4982):805-8.
View in:
PubMed
Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest. 1990 Oct; 86(4):1261-9.
View in:
PubMed
The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15; 76(4):716-20.
View in:
PubMed
Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990 Aug 15; 76(4):706-15.
View in:
PubMed
Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem. 1990 Jul 25; 265(21):12656-63.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol. 1990 Jul 15; 145(2):576-84.
View in:
PubMed
Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization. Leukemia. 1990 Jul; 4(7):466-70.
View in:
PubMed
Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? J Clin Oncol. 1990 May; 8(5):761-4.
View in:
PubMed
Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A. 1990 Apr; 87(7):2770-4.
View in:
PubMed
The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5.
View in:
PubMed
Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):93-7.
View in:
PubMed
Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41.
View in:
PubMed
Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989 Dec 01; 143(11):3543-7.
View in:
PubMed
Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 01; 56(3):425-30.
View in:
PubMed
Colony-stimulating factor gene expression in human acute myeloblastic leukemia cells is posttranscriptionally regulated. Leukemia. 1989 Sep; 3(9):620-5.
View in:
PubMed
Hemopoietins and leukemia. Hematol Oncol Clin North Am. 1989 Sep; 3(3):535-53.
View in:
PubMed
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15; 74(3):940-6.
View in:
PubMed
Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages. Leukemia. 1989 Jun; 3(6):405-12.
View in:
PubMed
Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood. 1989 May 15; 73(7):1951-6.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989 May; 3(5):328-34.
View in:
PubMed
Effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSFrh) on transmembrane electrical potentials in granulocytes: relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion (O2-) production. J Cell Physiol. 1989 May; 139(2):361-9.
View in:
PubMed
An elevation in the concentration of free cytosolic calcium is sufficient to activate the oxidative burst of granulocytes primed with recombinant human granulocyte-macrophage colony-stimulating factor. J Biol Chem. 1989 Apr 15; 264(11):6302-9.
View in:
PubMed
Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989 Apr 05; 264(10):5700-3.
View in:
PubMed
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr; 30(4):221-7.
View in:
PubMed
Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol. 1989 Apr; 71(4):475-9.
View in:
PubMed
Hemopoietins in oncology: factoring out myelosuppression. J Clin Oncol. 1989 Feb; 7(2):151-5.
View in:
PubMed
Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol. 1989 Jan 01; 142(1):139-43.
View in:
PubMed
Regulation of colony-stimulating factor production by normal and leukemic human cells. Immunol Res. 1989; 8(3):202-14.
View in:
PubMed
Infection of hematopoietic and stromal cells in human continuous bone marrow cultures by a retroviral vector containing the neomycin resistance gene. Acta Haematol. 1989; 82(3):136-43.
View in:
PubMed
Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family. Int Immunol. 1989; 1(4):388-97.
View in:
PubMed
Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. Haematol Blood Transfus. 1989; 32:299-315.
View in:
PubMed
Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. Blood. 1989 Jan; 73(1):131-6.
View in:
PubMed
Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol. 1988 Dec; 11(6):623-6.
View in:
PubMed
Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes. Blood. 1988 Nov; 72(5):1665-73.
View in:
PubMed
Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. Exp Hematol. 1988 Nov; 16(10):865-70.
View in:
PubMed
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8.
View in:
PubMed
Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7.
View in:
PubMed
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol. 1988 Jul 15; 141(2):575-9.
View in:
PubMed
Regulation of the production and function of granulocytes and monocytes. Semin Hematol. 1988 Jul; 25(3):173-88.
View in:
PubMed
Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood. 1988 Jun; 71(6):1529-32.
View in:
PubMed
In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82.
View in:
PubMed
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8.
View in:
PubMed
Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med. 1988 May 05; 318(18):1153-8.
View in:
PubMed
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest. 1988 Apr; 81(4):1030-5.
View in:
PubMed
Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TU 67). Blut. 1988 Apr; 56(4):179-83.
View in:
PubMed
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 1988 Mar; 71(3):672-6.
View in:
PubMed
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988 Feb; 81(2):624-9.
View in:
PubMed
Clinical applications of colony-stimulating factors. Oncology (Williston Park). 1988 Jan; 2(1):15-23.
View in:
PubMed
The biology of acute myeloblastic leukemia. Semin Oncol. 1987 Dec; 14(4):365-71.
View in:
PubMed
Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol. 1987 Nov 15; 139(10):3422-30.
View in:
PubMed
Growth factors required for proliferation of clonogenic cells in acute myeloblastic leukemia (AML). Haematologica. 1987 Nov-Dec; 72(6 Suppl):85-8.
View in:
PubMed
Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987 Oct; 70(4):1218-21.
View in:
PubMed
Acquisition of formyl peptide receptors during normal human myeloid differentiation. Blood. 1987 Oct; 70(4):1222-4.
View in:
PubMed
Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia. 1987 Aug; 1(8):584-9.
View in:
PubMed
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8.
View in:
PubMed
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987 Jun; 69(6):1771-6.
View in:
PubMed
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. Semin Oncol. 1987 Jun; 14(2 Suppl 1):149-58.
View in:
PubMed
Expression of the M-CSF (CSF-1) gene by human monocytes. Blood. 1987 May; 69(5):1409-13.
View in:
PubMed
Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987 May; 106(2):355-65.
View in:
PubMed
Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987 Apr 30; 316(18):1111-7.
View in:
PubMed
Southern blot analysis of BII cell line--a putative variant of HL-60. Leukemia. 1987 Feb; 1(2):142-5.
View in:
PubMed
The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate. J Biol Chem. 1987 Jan 25; 262(3):1274-81.
View in:
PubMed
Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest. 1987 Jan; 79(1):100-6.
View in:
PubMed
Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan; 17(1):153-6.
View in:
PubMed
Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. Haematol Blood Transfus. 1987; 31:185-90.
View in:
PubMed
The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematol Pathol. 1987; 1(2):81-91.
View in:
PubMed
In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood. 1987 Jan; 69(1):246-54.
View in:
PubMed
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1232-41.
View in:
PubMed
Clonogenic cells in acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1185-95.
View in:
PubMed
Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J Immunol. 1986 Nov 15; 137(10):3259-63.
View in:
PubMed
Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood. 1986 Nov; 68(5):1178-81.
View in:
PubMed
The role of colony stimulating factors in leukaemogenesis. Clin Haematol. 1986 Nov; 15(4):995-1002.
View in:
PubMed
Biology of acute myeloid leukaemia. Clin Haematol. 1986 Aug; 15(3):641-67.
View in:
PubMed
Management of chronic myelogenous leukemia. Semin Hematol. 1986 Jul; 23(3 Suppl 1):20-6.
View in:
PubMed
Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood. 1986 May; 67(5):1448-53.
View in:
PubMed
T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol. 1986 Apr 15; 136(8):2856-61.
View in:
PubMed
Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood. 1986 Apr; 67(4):898-902.
View in:
PubMed
Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol. 1986 Mar 01; 136(5):1629-34.
View in:
PubMed
Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest. 1986 Jan; 77(1):13-20.
View in:
PubMed
A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions. J Exp Med. 1985 Dec 01; 162(6):2035-52.
View in:
PubMed
TPA induces differentiation of purified human myeloblasts in the absence of proliferation. Exp Hematol. 1985 Nov; 13(10):1025-32.
View in:
PubMed
Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. Scand J Haematol. 1985 Oct; 35(4):408-17.
View in:
PubMed
Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood. 1985 Oct; 66(4):788-95.
View in:
PubMed
Clonogenic cells in acute myeloblastic leukaemia. Scand J Haematol. 1985 Sep; 35(3):251-6.
View in:
PubMed
Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol. 1985 Sep; 12(3):281-8.
View in:
PubMed
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 01; 162(3):1111-6.
View in:
PubMed
Detection of nonrandom clustering of colonies in agar culture. Exp Hematol. 1985 Aug; 13(7):696-700.
View in:
PubMed
Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. Exp Hematol. 1985 Jul; 13(6):560-5.
View in:
PubMed
Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol. 1985 Jul; 3(7):982-91.
View in:
PubMed
Amsacrine in refractory acute leukemia. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):787-9.
View in:
PubMed
Mb1, a plasma membrane antigen selectively expressed by U-937 cells. Blood. 1985 Jul; 66(1):135-42.
View in:
PubMed
Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9. Hematol Oncol. 1985 Jul-Sep; 3(3):179-86.
View in:
PubMed
Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol. 1985 Jun; 12(2 Suppl 3):200-7.
View in:
PubMed
Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest. 1985 May; 75(5):1690-5.
View in:
PubMed
Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1985 Mar; 75(3):1008-14.
View in:
PubMed
Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. Cancer Res. 1985 Mar; 45(3):1026-32.
View in:
PubMed
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
View in:
PubMed
Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest. 1985 Feb; 75(2):746-53.
View in:
PubMed
Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. Blood. 1985 Feb; 65(2):414-22.
View in:
PubMed
Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester. Leuk Res. 1985; 9(1):11-7.
View in:
PubMed
Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
View in:
PubMed
A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. Blood. 1984 Apr; 63(4):800-2.
View in:
PubMed
Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. Blood. 1984 Apr; 63(4):904-11.
View in:
PubMed
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984; 8(4):521-34.
View in:
PubMed
Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983 Dec 29; 309(26):1599-602.
View in:
PubMed
Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. Blood. 1983 Dec; 62(6):1300-3.
View in:
PubMed
Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). Cancer Genet Cytogenet. 1983 Oct; 10(2):167-75.
View in:
PubMed
Microgranular acute promyelocytic leukemia diagnosed by flow cytometry. N Engl J Med. 1983 Aug 18; 309(7):435.
View in:
PubMed
Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Methods. 1983 Jul 29; 61(3):283-92.
View in:
PubMed
Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983 Jul; 131(1):232-7.
View in:
PubMed
Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. Ann Intern Med. 1983 Jun; 98(6):926-7.
View in:
PubMed
Characterization of an antigen expressed by human natural killer cells. J Immunol. 1983 Jun; 130(6):2947-51.
View in:
PubMed
Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
View in:
PubMed
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood. 1983 Apr; 61(4):640-4.
View in:
PubMed
Conservation of myeloid surface antigens on primate granulocytes. Blood. 1983 Feb; 61(2):408-10.
View in:
PubMed
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
View in:
PubMed
Electrocardiogram abnormalities induced by amsacrine. Cancer Chemother Pharmacol. 1983; 10(2):133-4.
View in:
PubMed
Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C). Leuk Res. 1983; 7(1):43-9.
View in:
PubMed
Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in:
PubMed
Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. Blood. 1982 Jul; 60(1):30-7.
View in:
PubMed
Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen. Cell. 1982 Jan; 28(1):125-34.
View in:
PubMed
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
View in:
PubMed
Eye toxicity of cancer chemotherapy: a review of the literature. Cancer. 1981 Oct 01; 48(7):1539-49.
View in:
PubMed
Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
View in:
PubMed
Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
View in:
PubMed
A blast subclone of the HL-60 human promyelocytic cell line. Leuk Res. 1981; 5(4-5):429-30.
View in:
PubMed
Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells. J Virol. 1980 Nov; 36(2):488-98.
View in:
PubMed
Enzymatic activities associated with the SV40 large T antigen. Cold Spring Harb Symp Quant Biol. 1980; 44 Pt 1,:113-22.
View in:
PubMed
Protein kinase activity associated with simian virus 40 T antigen. Proc Natl Acad Sci U S A. 1979 Jun; 76(6):2610-4.
View in:
PubMed
Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen. Cell. 1978 Aug; 14(4):983-94.
View in:
PubMed
Measurements of the molecular size of the simian virus 40 large T antigen. J Virol. 1978 Jul; 27(1):218-26.
View in:
PubMed
Lymphocytic thymoma associated with T-cell lymphocytosis. Am J Med. 1978 Jun; 64(6):1075-9.
View in:
PubMed
Development of a histiocytic medullary reticulosis-like syndrome during the course of acute lymphocytic leukemia. Am J Med. 1978 May; 64(5):851-8.
View in:
PubMed
Epsilon-aminocaproic acid (EACA). Semin Thromb Hemost. 1978; 5(1):27-40.
View in:
PubMed
Ouabain antagonism of smooth muscle contraction. J Pharmacol Exp Ther. 1972 Sep; 182(3):378-87.
View in:
PubMed
Methylxanthine-induced escalation: a propagated wave phenomenon observed in skeletal muscle developing in culture. Proc Natl Acad Sci U S A. 1972 Mar; 69(3):613-6.
View in:
PubMed